<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>Drug Resistance</title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>


<div class="uk-container">
    <div>
        <div class="chapter-header">
            <div class="header-title">
                <div>
                    <img src="ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                </div>
                <p class="chapter-title">Drug Resistance</p>
            </div>
            <p class="last-updated"><i>Last Updated June 2024</i></p>
        </div>
        <hr>
    </div>
    <p class="uk-paragraph">
        Seek expert consultation for all patients with suspected or proven drug-resistant TB. Treatment of active TB disease caused by drug- resistant organisms should be done by or in close consultation with an expert in the management of these difficult situations.
    </p> 

    <p class="uk-paragraph">
        INH-resistant TB is the most common form of drug-resistant TB (with a global prevalence of >10%). Updated ATS/CDC/ IDSA recommendations for the treatment of drug-resistant TB recommend the addition of later generation fluoroquinolones (i.e., levofloxacin or moxifloxacin) to rifampin, pyrazinamide, and ethambutol for the treatment of INH-resistant TB, although there are limited data on the benefit of the addition of the fluoroquinolone in these circumstances.
    </p>
        
    <p class="uk-paragraph">
        Multidrug-resistant (MDR)-TB is defined as resistance to at least INH and rifampin. New and repurposed anti-TB drugs included in treatment regimens have provided new options for the treatment of MDR-TB including 6-9 month regimens using BPaL (bedaquiline, pretomanid, and levofloxacin) or BPaLM (BPaL plus moxifloxacin).
    </p>
    <p class="uk-paragraph">
        As
        noted, consultation with an expert is required for MDR-TB and other drug-resistant TB cases. Second line
        treatment
        regimens often represent the patientâ€™s last best hope for being cured. Inappropriate management can have
        life-threatening consequences.</p>
        <p class="uk-paragraph">
            If you think, identify, or suspect rifampin-resistant or MDR-TB disease in a person with TB, contact the state consultants by direct email, Dr. Susan Ray <a href="mailto:sray02@emory.edu">sray02@emory.edu</a> or Dr. Marcos Schechter <a href="mailto:mcoutin@emory.edu">mcoutin@emory.edu</a>, or by telephoning the Georgia Department of Public Health TB Program at 404-657-2597 for diagnostic and treatment support. There are multiple strategies to pursue rapid genotypic assessment for drug resistance.
        </p>
        <p class="uk-paragraph">Additionally, there are 
        several exciting new regimens with strong outcomes that require expert consultation.
        See <a href="15_appendix_district_tb_coordinators_(by_district).html">Appendix</a> and/or website for making contact with an appropriate expert in
        your
        county:<a href="https://dph.georgia.gov/district-health-directors">https://dph.georgia.gov/district-health-directors</a>
    </p>

</div>

</body>

<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
</html>
